Patrik Jeanmonod, Chief Financial Officer at Cytek Biosciences, Inc. (CTKB), sold 3,500 shares at $9.77 ($34K) on 2022-12-27, disclosed to the SEC on 2022-12-29.
Scheduled sale ($34k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CTKB | SELL | 2023-10-25 | $14K | — | Filing → |
| CTKB | SELL | 2023-09-26 | $19K | — | Filing → |
| CTKB | SELL | 2023-08-28 | $23K | — | Filing → |